GB201817047D0 - H4 antagonist compounds - Google Patents
H4 antagonist compoundsInfo
- Publication number
- GB201817047D0 GB201817047D0 GBGB1817047.2A GB201817047A GB201817047D0 GB 201817047 D0 GB201817047 D0 GB 201817047D0 GB 201817047 A GB201817047 A GB 201817047A GB 201817047 D0 GB201817047 D0 GB 201817047D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- antagonist compounds
- antagonist
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003396 histamine H4 receptor antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1817047.2A GB201817047D0 (en) | 2018-10-19 | 2018-10-19 | H4 antagonist compounds |
| CN201980084053.7A CN113272297B (zh) | 2018-10-19 | 2019-10-21 | 作为h4拮抗剂化合物的吡唑衍生物 |
| ES19794235T ES3058587T3 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
| BR112021007372-8A BR112021007372A2 (pt) | 2018-10-19 | 2019-10-21 | derivados de pirazol como compostos antagonistas de h4 |
| KR1020217014805A KR102873380B1 (ko) | 2018-10-19 | 2019-10-21 | H4 길항제 화합물 |
| AU2019360428A AU2019360428B2 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as H4 antagonist compounds |
| JP2021521390A JP7532353B2 (ja) | 2018-10-19 | 2019-10-21 | Ｈ４アンタゴニスト化合物としてのピラゾール誘導体 |
| CA3116628A CA3116628A1 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
| MX2021004280A MX2021004280A (es) | 2018-10-19 | 2019-10-21 | Derivados de pirazol como compuestos antagonistas de receptor de histamina h4. |
| US17/285,776 US12234227B2 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as H4 antagonist compounds |
| PCT/GB2019/052997 WO2020079457A1 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
| SG11202103133QA SG11202103133QA (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
| EP19794235.2A EP3867248B1 (en) | 2018-10-19 | 2019-10-21 | Pyrazole derivatives as h4 antagonist compounds |
| US18/826,098 US20250115587A1 (en) | 2018-10-19 | 2024-09-05 | Pyrazole derivatives as h4 antagonist compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1817047.2A GB201817047D0 (en) | 2018-10-19 | 2018-10-19 | H4 antagonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201817047D0 true GB201817047D0 (en) | 2018-12-05 |
Family
ID=64453795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1817047.2A Ceased GB201817047D0 (en) | 2018-10-19 | 2018-10-19 | H4 antagonist compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12234227B2 (https=) |
| EP (1) | EP3867248B1 (https=) |
| JP (1) | JP7532353B2 (https=) |
| KR (1) | KR102873380B1 (https=) |
| CN (1) | CN113272297B (https=) |
| AU (1) | AU2019360428B2 (https=) |
| BR (1) | BR112021007372A2 (https=) |
| CA (1) | CA3116628A1 (https=) |
| ES (1) | ES3058587T3 (https=) |
| GB (1) | GB201817047D0 (https=) |
| MX (1) | MX2021004280A (https=) |
| SG (1) | SG11202103133QA (https=) |
| WO (1) | WO2020079457A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005858D0 (en) * | 2020-04-22 | 2020-06-03 | Heptares Therapeutics Ltd | H4 Antagonist compounds |
| GB202019667D0 (en) * | 2020-12-14 | 2021-01-27 | Heptares Therapeutics Ltd | H4 antagonist comnpounds |
| WO2022203399A1 (ko) * | 2021-03-26 | 2022-09-29 | 주식회사 스탠다임 | 아데노신 a2a 수용체 길항제 및 이의 용도 |
| WO2022232259A1 (en) * | 2021-04-28 | 2022-11-03 | Cornell University | Soluble adenylyl cyclase (sac) inhibitors and uses thereof |
| EP4421067A4 (en) * | 2021-10-19 | 2026-01-14 | Unimatec Co Ltd | PYRAZOLE COMPOUND CONTAINING FLUORIDE AND ITS PRODUCTION PROCESS |
| KR102621694B1 (ko) * | 2022-09-15 | 2024-01-08 | 주식회사 스탠다임 | 아데노신 a2a 수용체 길항제 및 이의 용도 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000169475A (ja) | 1998-07-24 | 2000-06-20 | Dai Ichi Seiyaku Co Ltd | ピラゾ―ル誘導体およびその塩 |
| US6573377B1 (en) * | 1998-07-24 | 2003-06-03 | Daiichi Pharmaceuticals Co., Ltd. | Pyrazole derivatives and salts thereof |
| WO2005054239A1 (en) | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
| NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| US20100035863A1 (en) | 2006-09-12 | 2010-02-11 | Ucb Pharma, S.A. | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions |
| US7985745B2 (en) * | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
| CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
| WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
| PE20091524A1 (es) | 2007-12-19 | 2009-09-25 | Palau Pharma Sa | Derivados de 2-aminopirimidina |
| CN101903385B (zh) | 2007-12-21 | 2013-11-06 | 帕劳制药股份有限公司 | 作为组胺h4受体拮抗剂的4-氨基嘧啶衍生物 |
| AR074199A1 (es) * | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
| TW201035078A (en) | 2009-03-20 | 2010-10-01 | Incyte Corp | Substituted heterocyclic compounds |
| MX2012004995A (es) | 2009-10-29 | 2012-10-03 | Sirtris Pharmaceuticals Inc | Piridinas biciclicas y analogos como moduladores de sirtuina. |
| WO2011076878A1 (en) | 2009-12-23 | 2011-06-30 | Palau Pharma, S.A. | Aminoalkylpyrimidine derivatives as histamine h4 receptor antagonists |
| US9580443B2 (en) | 2012-11-16 | 2017-02-28 | Merck Patent Gmbh | Heterocyclic derivatives as modulators of kinase activity |
| US11401255B2 (en) | 2016-07-28 | 2022-08-02 | Mayo Foundation For Medical Education And Research | Small molecule activators of Parkin enzyme function |
-
2018
- 2018-10-19 GB GBGB1817047.2A patent/GB201817047D0/en not_active Ceased
-
2019
- 2019-10-21 US US17/285,776 patent/US12234227B2/en active Active
- 2019-10-21 SG SG11202103133QA patent/SG11202103133QA/en unknown
- 2019-10-21 CN CN201980084053.7A patent/CN113272297B/zh active Active
- 2019-10-21 AU AU2019360428A patent/AU2019360428B2/en active Active
- 2019-10-21 JP JP2021521390A patent/JP7532353B2/ja active Active
- 2019-10-21 ES ES19794235T patent/ES3058587T3/es active Active
- 2019-10-21 EP EP19794235.2A patent/EP3867248B1/en active Active
- 2019-10-21 MX MX2021004280A patent/MX2021004280A/es unknown
- 2019-10-21 KR KR1020217014805A patent/KR102873380B1/ko active Active
- 2019-10-21 CA CA3116628A patent/CA3116628A1/en active Pending
- 2019-10-21 BR BR112021007372-8A patent/BR112021007372A2/pt unknown
- 2019-10-21 WO PCT/GB2019/052997 patent/WO2020079457A1/en not_active Ceased
-
2024
- 2024-09-05 US US18/826,098 patent/US20250115587A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3867248B1 (en) | 2025-12-10 |
| KR102873380B1 (ko) | 2025-10-23 |
| CA3116628A1 (en) | 2020-04-23 |
| EP3867248A1 (en) | 2021-08-25 |
| CN113272297B (zh) | 2024-03-19 |
| US20250115587A1 (en) | 2025-04-10 |
| WO2020079457A1 (en) | 2020-04-23 |
| US20210300906A1 (en) | 2021-09-30 |
| US12234227B2 (en) | 2025-02-25 |
| SG11202103133QA (en) | 2021-05-28 |
| CN113272297A (zh) | 2021-08-17 |
| ES3058587T3 (en) | 2026-03-11 |
| KR20210079318A (ko) | 2021-06-29 |
| JP7532353B2 (ja) | 2024-08-13 |
| MX2021004280A (es) | 2021-05-31 |
| AU2019360428B2 (en) | 2024-05-09 |
| EP3867248C0 (en) | 2025-12-10 |
| JP2022507013A (ja) | 2022-01-18 |
| BR112021007372A2 (pt) | 2021-07-20 |
| AU2019360428A1 (en) | 2021-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201810092D0 (en) | Compounds | |
| GB201805174D0 (en) | Compounds | |
| GB201801355D0 (en) | Compounds | |
| GB201807924D0 (en) | Compounds | |
| GB201817047D0 (en) | H4 antagonist compounds | |
| GB201810581D0 (en) | Compounds | |
| IL279620A (en) | compounds | |
| GB201808093D0 (en) | Compounds | |
| GB201812382D0 (en) | Compounds | |
| GB201814151D0 (en) | Compounds | |
| GB201809102D0 (en) | Compounds | |
| GB201818651D0 (en) | Compounds | |
| GB201818649D0 (en) | Compounds | |
| GB201817083D0 (en) | Compounds | |
| GB201814167D0 (en) | Compounds | |
| GB201810071D0 (en) | Compounds | |
| GB201803340D0 (en) | Compounds | |
| GB201801128D0 (en) | Compounds | |
| GB201801130D0 (en) | Compounds | |
| GB201918392D0 (en) | H4 Antagonist compounds | |
| GB201901868D0 (en) | H4 antagonist compounds | |
| GB201910865D0 (en) | Antagonist compounds | |
| GB201812604D0 (en) | Antagonist compounds | |
| GB201904158D0 (en) | Antagonist compounds | |
| GB201910526D0 (en) | Antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |